MedImmune announces in-licensing agreement with Progenics

theflyonthewall.com

MedImmune announced that it has signed an in-licensing agreement with Progenics Pharmaceuticals for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines Unit. Financial details of the agreement were not disclosed.

View Comments (0)